EUVIMEDEUVIMED entdecken
Crossref

Antileishmanial and Antitrypanosomal Trends of Synthetic Tetralone Derivatives

Abdulsalam A M Alkhaldi, Harry P de Koning, Syed Nasir Abbas Bukhari

Drug Development Research · 2025

DOI: 10.1002/ddr.70055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Abdulsalam A M Alkhaldi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biology Department, College of Science, Jouf University, Sakaka, Aljouf, Saudi Arabia. Hauptthemen laut MEDLINE: Trypanosoma brucei brucei, Antiprotozoal Agents, Tetralones, Trypanocidal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: This work was funded by the Deanship of Graduate Studies and Scientific Research at Jouf University under grant No. (DGSSR-2023-01-02210)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leishmaniasis and trypanosomiasis are parasitic diseases that are closely linked to poverty, pose significant local burdens, and are common in tropical and subtropical regions. Various synthetic tetralone derivatives were studied as potential scaffolds for antileishmanial and antitrypanosomal activities. The compounds were studied for their effectiveness against multiple kinetoplastid protozoan pathogens: Leishmania major , Leishmania mexicana, and bloodstream trypomastigotes of Trypanosoma brucei brucei . Two different strains of T. b. brucei were used. The first strain was the wild‐type Trypanosoma brucei (s427‐WT), and the second strain was the multidrug resistant (MDR) strain B48, which was produced by deleting the TbAT1 gene from s427WT and subsequent adaptation to high levels of resistance to diamidines and organo‐arsenical drugs. Compounds 4c, 7c, 9b , and 11b showed activity against two strains of Trypanosoma and two different Leishmania species, establishing them as versatile leads with broad anti‐kinetoplastid activity. Compound 4c , a tetralone derivative with a bromo‐containing trimethoxybenzylidene moiety and methyl‐substituted cyclohexanone ring, was identified as the most potent inhibitor for both T. b. brucei strains, with EC 50 values of 0.19 and 0.22 µM for WT and B48, respectively, showing the absence of cross‐resistance with the diamidine and arsenical trypanocide classes. In addition, compound 4c exhibited more potency than both controls, eflornithine and pentamidine, against the MDR strain. We conclude that tetralone derivates could be a valuable starting point for the discovery of new antiparasitic drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trypanosoma brucei bruceiAntiprotozoal AgentsTetralonesTrypanocidal AgentsAnimalsParasitic Sensitivity TestsLeishmania mexicanaLeishmania majorStructure-Activity Relationship

Stichwörter der Autor:innen

cyclohexanoneprotozoan parasitessleeping sicknesssynthesiszoonotic vector‐borne disease

Substanzen

Antiprotozoal AgentsTetralonesTrypanocidal Agents

Autor:innen und Institutionen

  • Biology Department, College of Science, Jouf University, Sakaka, Aljouf, Saudi Arabia.
  • School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Aljouf, Saudi Arabia.

Förderung

  • This work was funded by the Deanship of Graduate Studies and Scientific Research at Jouf University under grant No. (DGSSR-2023-01-02210).

Zitieren

APA

Alkhaldi, A. A. M., de Koning, H. P., & Bukhari, S. N. A. (2025). Antileishmanial and Antitrypanosomal Trends of Synthetic Tetralone Derivatives. Drug Development Research. https://doi.org/10.1002/ddr.70055

Vancouver

Alkhaldi AAM, de Koning HP, Bukhari SNA. Antileishmanial and Antitrypanosomal Trends of Synthetic Tetralone Derivatives. Drug Development Research. 2025. doi:10.1002/ddr.70055

BibTeX
@article{Alkhaldi2025,
  author = {Alkhaldi, Abdulsalam A M and de Koning, Harry P and Bukhari, Syed Nasir Abbas},
  title = {Antileishmanial and Antitrypanosomal Trends of Synthetic Tetralone Derivatives},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70055}
}
Kostenlos starten →